Home > Dermatology > SPIN 2022 > Psoriasis: The Beat Goes On > IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab

IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab

Conference
SPIN 2022
Trial
Phase 3, BE RADIANT
Doi
https://doi.org/10.55788/fa17ee49
An analysis of the long-term efficacy of bimekizumab versus secukinumab found greater proportions of response and maintenance for the IL17A/F inhibitor. In the phase 3b BE RADIANT trial, 88.0% of bimekizumab and 79.1% of secukinumab responders reaching a Psoriasis Area and Severity Index (PASI) ≤2 at week 16 upheld response to week 48. Data obtained from psoriatic patients has revealed that not only the achievement of clear or almost clear skin is very important, but also the durability of the therapy effect [1,2]. With this in mind, a post-hoc analysis of the phase 3b, head-to-head BE RADIANT trial (NCT03536884) was performed, which evaluated participants achieving a PASI ≤2 or 0 on bimekizumab or secukinumab at week 16 in their ability to maintain the response continuously through week 48 [3]. After randomisation, 743 trial participants received either...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on